ProCE Banner Activity

Expert Perspectives on Therapeutic Advances to Improve Treatment, Clinical Outcomes, and Quality of Life of Veterans With NSCLC

Multimedia
Review critical updates that may improve the care of patients with advanced NSCLC in this archived presentation of a meeting in the VHA system.

Released: March 18, 2019

Expiration: March 16, 2020

No longer available for credit.

Share

Faculty

Joshua Bauml

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

AstraZeneca Pharmaceuticals

Celgene TEXT Only

Faculty Disclosure

Primary Author

Joshua Bauml, MD

Instructor, Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Staff Physician
Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Joshua Bauml, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Guardant Health, and Merck and funds for research support from Bayer, Incyte, Janssen, Merck, and Novartis.